David Mauro
Chief Tech/Sci/R&D Officer bei RECURSION PHARMACEUTICALS, INC.
Vermögen: 2 Mio $ am 31.03.2024
Profil
Gegenwärtig hat David J. Mauro die Position des Chief Medical Officer bei Prelude Therapeutics, Inc. inne. Zuvor hatte Dr. Mauro die Position des Chief Medical Officer & Executive Vice President bei Advaxis, Inc. und des Chief Medical Officer bei Checkmate Pharmaceuticals, Inc. inne. Dr. Mauro erwarb einen Bachelor-Abschluss an der Cornell University und einen Doktortitel an der Temple University School of Medicine.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
09.02.2024 | 244 629 ( 0,12% ) | 2 Mio $ | 31.03.2024 |
Aktive Positionen von David Mauro
Unternehmen | Position | Beginn |
---|---|---|
RECURSION PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01.06.2023 |
Ehemalige bekannte Positionen von David Mauro
Unternehmen | Position | Ende |
---|---|---|
CODIAK BIOSCIENCES | Chief Tech/Sci/R&D Officer | 07.04.2023 |
CHECKMATE PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 15.10.2019 |
AYALA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01.02.2016 |
MERCK & CO., INC. | Director/Board Member | 01.01.2014 |
BRISTOL-MYERS SQUIBB COMPANY | Director/Board Member | - |
Ausbildung von David Mauro
Cornell University | Undergraduate Degree |
Temple University School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 4 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
MERCK & CO., INC. | Health Technology |
RECURSION PHARMACEUTICALS, INC. | Health Technology |
PRELUDE THERAPEUTICS INCORPORATED | Health Technology |
Private Unternehmen | 3 |
---|---|
Advaxis, Inc.
Advaxis, Inc. Pharmaceuticals: MajorHealth Technology Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ. | Health Technology |
Checkmate Pharmaceuticals, Inc.
Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
Codiak BioSciences, Inc.
Codiak BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Codiak BioSciences, Inc. engages in the development and manufacturing of exosomes. It engages in harnessing exosomes, therapeutic applications, diagnostic applications, and proprietary production. The firm develops engEx Platform, a proprietary and versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. Codiak BioSciences was founded by Douglas E. William, Raghu Kalluri, and Eric S. Lander in 2015 and is headquartered in Cambridge, MA. | Health Technology |